Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation

Leuk Res. 2021 Oct:109:106648. doi: 10.1016/j.leukres.2021.106648. Epub 2021 Jun 23.

Authors

Meera Mohan¹, Parameswaran Hari², Aniko Szabo², Binod Dhakal², Saurabh Chhabra², Anita D'Souza²

Affiliations

¹ Medical College of Wisconsin, United States. Electronic address: [email protected].
² Medical College of Wisconsin, United States.

PMID: 34182226
DOI: 10.1016/j.leukres.2021.106648

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Combined Modality Therapy
Consolidation Chemotherapy / mortality*
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation / mortality*
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Multiple Myeloma / therapy
Prognosis
Survival Rate
Transplantation, Autologous

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab

Associated data

ClinicalTrials.gov/NCT04436029
ClinicalTrials.gov/NCT04140162
ClinicalTrials.gov/NCT04876248